Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 27, 2015 9:09 PM ET

Healthcare Equipment and Supplies

Company Overview of Oncimmune Limited

Company Overview

Oncimmune Limited develops and commercializes products for the detection of cancerous tumors. It offers EarlyCDT that detects and measures auto antibodies that immune system produces in response to antigens generated by cancerous tumors; and EarlyCDT-Lung, a blood test that detects the body's immune response in the form of antibodies to certain proteins produced by cancer cells. The company was incorporated in 2002 and is based in Nottingham, the United Kingdom.

Clinical Sciences Building

Nottingham City Hospital

Hucknall Road

Nottingham,  NG5 1PB

United Kingdom

Founded in 2002

Phone:

44 1158 231 869

Fax:

44 1158 231 958

Key Executives for Oncimmune Limited

Chief Executive Officer
Clinical Director
Compensation as of Fiscal Year 2015.

Oncimmune Limited Key Developments

Glycotest, Inc. Enters into a Research Collaboration with Oncimmune Ltd

NetScientific announced its portfolio company Glycotest, Inc. has entered into a research collaboration with Oncimmune Ltd. to explore the combined application of their proprietary tests in the early detection of liver cancer. Oncimmune has previously commercialised its proprietary autoantibody assay technology for the early detection of lung cancer with its EarlyCDT-Lung test and is now expanding this technology to the detection of liver cancer as well as other solid tumour cancers.  Glycotest is developing proprietary glycoprotein biomarkers and assay technology for the surveillance of serious liver diseases, including liver cancer. Under the terms of the agreement, Glycotest and Oncimmune will conduct a joint clinical evaluation of their combined tests, which could then be co-developed as agreed by the collaborators.

Oncimmune Limited Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 08:30 AM

Oncimmune Limited Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 08:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Geoffrey Hamilton Fairley, Exec Chairman.

Similar Private Companies By Industry

Company Name Region
T.J. Smith & Nephew, Limited Europe
TiGenix Limited Europe
Hartest Holdings plc Europe
Drive Medical Limited Europe
W H Promation Limited Europe

Recent Private Companies Transactions

Type
Date
Target
Bankruptcy
June 7, 2015
Health Diagnostic Laboratory, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oncimmune Limited, please visit www.earlycdt-lung.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.